Trial Profile

A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sargramostim (Primary)
Indications Acute myeloid leukaemia
Focus Pharmacodynamics
Sponsors Sanofi; Sanofi Genzyme

Most Recent Events

31 Jul 2023 This study has been completed in Czech Republic, according to European Clinical Trials Database.
29 Mar 2017 Planned End Date changed from 1 Jul 2022 to 28 Feb 2017.
29 Mar 2017 Planned primary completion date changed from 1 Jul 2022 to 28 Feb 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com